MITO39: Efficacy and Tolerability of Pegylated Liposomal Doxorubicin (PLD)–Trabectedin in the Treatment of Relapsed Ovarian Cancer after Maintenance Therapy with PARP Inhibitors—A Multicenter Italian Trial in Ovarian Cancer Observational Case-Control Study
Academic Article
Publication Date:
2024
Iris type:
1.1 Articolo in rivista
List of contributors:
Turinetto, M.; Ricotti, A.; Marchetti, C.; Pisano, C.; Zamagni, C.; Cassani, C.; Malaguti, P.; Baldoni, A.; Scollo, P.; Scandurra, G.; Parisi, A.; Artioli, G.; Palaia, I.; Vertechy, L.; Bergamini, A.; Picardo, E.; Tuninetti, V.; Scotto, G.; Scambia, G.; Pignata, S.; Valabrega, G.
Published in: